PACT & HEALTH LLC — Department of Health and Human Services SBIR Phase II: NCI

Description

Tumor Irradiation during cancer treatment induces clonogenic death that can be best assessed by colony forming assaysThese colony forming assays are laborious and never utilized in high throughput screeningHTSformatsWe propose to develop anintegrated platform for HTS clonogenic survival assayfor cancer drug screening as well as radiation effect modulation screeningNamedI PARTSIntegrated platform for anti cancer radiation therapeutics screening combines the recent technological advances in cell culture automationmicrofluidicsand high speed image analysis along with NIST traceable dosimetry based HTS X ray irradiationThe I PARTS adopts modular multimodal microscopy to capture the real time colony growth with phase contrastluminescencefluorescence or physical features through tomographyCommerciallythe product has the scope and feasibility to analyze various cancer drugs with variable X ray dosesand simultaneously in different cell linesFutherthis novel single cell array clonogenic platforms will allow improved plating efficiency in clonogenic assay systemsExperimental validation and commercialization will be pursued during this proposalI PARTSan integrated instrument is designed and developed to discover new cancer drugs required for combined cancer therapyThis instrument and the technology is miniaturized such that cancer drugs and radiation treatment can be tailored for individual patientsthe ongoing goal of personalized medicine